Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

DOR Based on Investigator's Assessment per RECIST v1.1

Time frame: Up to Approximately 5 Years

DCR Based on Investigator's Assessment per RECIST v1.1

Time frame: Up to Approximately 5 Years

TTR Based on Investigator's Assessment per RECIST v1.1

Time frame: Up to Approximately 5 Years

Depth of Response Based on Investigator's Assessment per RECIST v1.1

Time frame: Up to Approximately 5 Years

Time to ETS Based on Investigator's Assessment per RECIST v1.1

Time frame: Up to Approximately 5 Years

Number of Participants Experiencing Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in participant or clinical investigation subject administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. A serious AE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgment may jeopardize the patient or may require medical or surgical intervention to prevent any of the outcomes listed above.

Time frame: Up to Approximately 5 Years

Pre-dose (Ctrough) Concentrations of Sotorasib

Time frame: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)

Maximum Plasma Concentration (Cmax) of Sotorasib

Time frame: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)